Trial Profile
Phase IIa trial of ISC-hpNSC in patients with Parkinson's disease
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 16 Mar 2016
Price :
$35
*
At a glance
- Drugs ISC-hpNSC (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors International Stem Cell Corporation
- 16 Mar 2016 New trial record
- 14 Apr 2015 According to a media release, International Stem Cell Corporation has submitted a CTX application to the Australian regulatory authorities and plans to initiate the trial within the next few months.